Securities Registration (section 12(b)) (8-a12b)
July 28 2015 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF
THE SECURITIES EXCHANGE ACT OF 1934
Benitec
Biopharma Limited
(Exact name of registrant as specified in its charter)
|
|
|
Australia |
|
Not Applicable |
(State of incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
F6A/1-15 Barr Street
Balmain, NSW, 2041, Australia
Tel: +61 2 9555 6986
(Address of principal executive offices)
Securities to
be registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class be
to be so registered |
|
Name of each exchange on which
each class is to be registered |
Ordinary Shares, no par value
American Depositary Shares,
each representing 20 Ordinary Shares |
|
The NASDAQ Stock Market LLC*
The NASDAQ Stock Market LLC |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General
Instruction A.(c), check the following box. x
If this form relates to the registration of a
class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. ¨
Securities Act registration statement file number to which this form relates: 333-205135
Securities to be registered pursuant to Section 12(g) of the Act: None
* |
Not for trading, but only in connection with the listing of the American Depositary Shares on The NASDAQ Global Select Market. The American Depositary Shares represent ordinary shares and are being registered under the
Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to
Rule 12a-8. |
ITEM 1. |
DESCRIPTION OF REGISTRANTS SECURITIES TO BE REGISTERED. |
The description
of the securities to be registered is set forth under the headings Description of Share Capital and Description of American Depositary Shares in the Registrants Registration Statement on Form F-1 (File
No. 333-205135), filed with the Securities and Exchange Commission on June 22, 2015, as subsequently amended by any amendments to such Registration Statement and by any form of prospectus filed pursuant to Rule 424(b) under the Securities
Act of 1933 in connection with such Registration Statement. Such Registration Statement, as amended, and any form of prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933 that includes such description, are hereby incorporated by
reference herein.
Pursuant to the Instructions as to Exhibits with respect to Form 8-A,
no exhibits are required to be filed because no other securities of the Registrant are registered on The NASDAQ Global Select Market and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities
Exchange Act of 1934.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this Registration
Statement to be signed on its behalf by the undersigned, thereto duly authorized.
|
|
|
Benitec Biopharma Limited |
|
|
By: |
|
/s/ Peter French |
Name: |
|
Peter French |
Title: |
|
Chief Executive Officer |
Dated: July 27, 2015